10-Q/A

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q/A

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2009

OR

¨ TRANSITION REPORT UNDER SECTION 13 OF 15(d) OF THE EXCHANGE ACT OF 1934

From the transition period from ____________ to ___________.

Commission File Number 000-50541

Oncolin Therapeutics, Inc.

(Exact name of small business issuer as specified in its charter)

(Former Name if Applicable)

Nevada	88-0507007
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification Number)

710 North Post Oak Suite 410, Houston, Texas 77024

(Address of principal executive offices)

(713) 780-0806

 (Issuer's telephone number)

Check whether the issuer has (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

Yes x         No ¨

Indicate by check mark whether the registrant is a large accelerated filer, and accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer  ¨	Accelerated filer   ¨
Non-accelerated filer  ¨	Smaller reporting company  x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act. Yes   ¨ No   x

As of May 19, 2010, there were outstanding 463,655,263 shares of common stock, $0.01 par value per share.

EXPLANATORY NOTE

This quarterly report on Form 10-Q is being filed as Amendment No. 1 to our Quarterly Report on Form 10-Q which was originally filed on May 14, 2010 with the Securities and Exchange Commission.  We are amending and restating our financial statements to record a year end adjustment that was inadvertently omitted from the March 31, 2009 financial statements included in our original filing.  The error occurred as a result of our simultaneously preparing delinquent Forms 10-K and 10-Q in order to become current in our SEC filings.  The adjustment is necessary so that the financial statements in this Form 10-Q are consistent with our financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2009, which was filed with the SEC on May 5, 2010.

Except as specifically referenced herein, this Amendment No. 1 to the Quarterly Report on Form 10-Q does not reflect any event occurring subsequent to May 14, 2010, the filing date of the original report.

ONCOLIN THERAPEUTICS, INC. AND SUBSIDIARIES

INDEX TO FORM 10-Q/A

September 30, 2009

Part I	Financial Information
	Item 1.	Financial Statements
		Consolidated Balance Sheets (unaudited) September 30, 2009 and March 31, 2009	3
		Consolidated Statements of Operations (unaudited) Three and Six Months Ended September 30, 2009 and 2008, and Inception (May 9, 2007) through September 30, 2009	4
		Consolidated Statements of Cash Flow (unaudited) Six Months Ended September 31, 2009 and 2008, and Inception (May 9, 2007) through September 30, 2009	5
		Notes to Unaudited Consolidated Financial Statements	6
	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	7
	Item 3.	Quantitative and Qualitative Disclosures About Market Risk	8
	Item 4.	Controls and Procedures	8
Part II	Other Information
	Item 5.	Exhibits	9

2

PART I.              FINANCIAL INFORMATION

ITEM 1.  FINANCIAL STATEMENTS

ONCOLIN THERAPEUTICS, INC. AND SUBSIDIARIES

(A DEVELOPMENT STAGE COMPANY)

CONSOLIDATED BALANCE SHEETS

(Unaudited)

	September30, 2009			March31, 2009
	(Restated)
ASSETS
Cash and cash equivalents	$	14		$	300
Total current assets		14			300
Property and equipment, net		3,487			4,002
Total assets	$	3,501			4,302
LIABILITIES AND SHAREHOLDERS' DEFICIT
Current liabilities:
Accounts payable	$	225,166			226,113
Accounts payable – related parties		102,173			102,173
Accrued liabilities		32,880			28,102
Notes payable – related parties		99,478			95,302
Total current liabilities		459,697			451,690
Shareholders deficit:
Common stock, $.001 par value, 500,000,000 shares authorized; 462,055,263 shares issued and outstanding		462,055			462,055
Additional paid-in capital		1,875,942			1,875,942
Deficit accumulated during the development stage		(2,794,193	)		(2,785,385	)
Total shareholders’ deficit		(456,196	)		(447,388	)
Total liabilities and shareholders' deficit	$	3,501			4,302

See accompanying notes to unaudited consolidated financial statements.

3

ONCOLIN THERAPEUTICS, INC. AND SUBSIDIARIES

(A DEVELOPMENT STAGE COMPANY)

CONSOLIDATED STATEMENTS OF OPERATIONS

 (Unaudited)

	ThreeMonthsEndedSeptember 30,						SixMonthsEndedSeptember 30,						Inception (May 9, 2007) to
	2009			2008			2009			2008			September 30, 2009
	(Restated)						(Restated)						(Restated)
Revenue	$	-		$	-		$	-		$	-		$	-
Costs and expenses:
Compensation and related expenses		-			36,000			-			87,800			1,009,324
Office administration		-			300			65			3,228			21,070
Professional fees		-			111,694			3,450			276,822			853,388
Investor relations		-			965			-			9,325			292,444
Merger expenses		-			-			-			-			8,113
Impairment of license agreement		-			32,725			-			32,725			80,100
Acquisition costs of subsidiary		-			-			-			-			220,000
Depreciation and amortization		258			4,668			515			11,556			30,547
Other expenses		-			3,048			-			35,012			292,026
Total costs and expenses		258			189,400			4,030			456,468			2,807,012
Interest expense		2,402			61,452			4,778			91,018			465,946
Gain on deconsolidated subsidiary		-			-			-			-			(478,765	)
Net  loss	$	(2,660	)	$	(250,852	)	$	(8,808	)	$	(547,486	)	$	(2,794,193	))
Net loss per share:
Basic and diluted	$	(0.00	)	$	(0.01	)	$	(0.00	)	$	(0.01	)
Weighted average number of common shares outstanding – Basic and diluted		462,055,263			42,549,654			462,055,263			42,969,887

See accompanying notes to unaudited consolidated financial statements.

4

ONCOLIN THERAPEUTICS, INC. AND SUBSIDIARIES

(A DEVELOPMENT STAGE COMPANY)

CONSOLIDATED STATEMENTS OF CASH FLOWS

 (Unaudited)

	SixMonthsEndedSeptember 30,						Cumulative fromInception (May9,2007) through
	2009			2008			September30, 2009
	(Restated)						(Restated)
Cash flows from operating activities:
Net income (loss)	$	(8,808	)	$	(547,486	)	$	(2,794,193	)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization		515			11,556			21,658
Amortization of deferred financing costs		-			2,502			15,000
Non-cash compensation expense relating to license agreement		-			-			119,900
Impairment of license agreement		-			32,725			80,100
Amortization of debt discount		-			71,504			397,985
Share-based compensation		-			58,750			913,481
Non-cash acquisition of subsidiary					-			220,000
Changes in assets and liabilities:
Other current assets					-			15,750
Accounts payable		(947	)		73,537			288,468
Accounts payable – related parties		-			45,499			102,173
Accrued liabilities		4,778			96,747			69,448
Net cash used in operating activities		(4,462	)		(154,666	)		(550,230	)
Cash flows from investing activities:
Investment in option agreement		-			-			(20,000	)
Property and equipment		-			-			(5,145	)
Net cash used in investing activities		-			-			(25,145	)
Cash flows from financing activities:
Proceeds from notes payable – related parties		4,176			-			227,176
Repayment of notes payable – related party		-			-			(13,000	)
Proceeds from sale of common stock		-			90,000			91,165
Proceeds from exercise of stock options		-			67,239			270,048
Net cash provided by financing activities		4,176			157,239			575,389
Net change in cash		(286	)		2,573			14
Cash and cash equivalents, beginning of period		300			1,174			-
Cash and cash equivalents, end of period	$	14		$	3,747		$	14
Supplemental disclosures:
Interest paid	$	-		$	-		$	5,633
Income taxes paid	$	-		$	-		$	-
Non-cash financing activities:
Discount on convertible notes	$	-		$	397,985		$	397,985
Stock issued for accounts payable		-			200,079			-
Cancellation of stock certificate		-			-			300
Short term debt issued for related party accounts payable		-			63,302			-
Issuance of note payable for license agreement		-			-			200,000
Stock issued for prepaid investor relation services		-			-			73,800
Conversion of Notes payable and Accrued Interest		-			-			414,568

See accompanying notes to unaudited consolidated financial statements.

5

ONCOLIN THERAPEUTICS, INC. AND SUBSIDIARIES

(A DEVELOPMENT STAGE COMPANY)

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2009

Note 1.   Basis of Presentation

The accompanying unaudited financial statements of Oncolin Therapeutics, Inc. (the "Company" or "Oncolin") have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X related to smaller reporting companies. These consolidated financial statements should be read in conjunction with the audited financial statements and notes, which are included as part of the Company's Form 10-K filed with the SEC on May 5, 2010.In the opinion of management, all adjustments, consisting only of normal recurring adjustments, considered necessary for a fair presentation, have been included in the accompanying unaudited consolidated financial statements.  Operating results for the periods presented are not necessarily indicative of the results that may be expected for the full year.  Notes to the financial statements which substantially duplicate the disclosure contained in the audited financial statements for fiscal year ended March 31, 2009 as reported in the 10-K have been omitted.

Note 2.   Going Concern

These financial statements have been prepared on a going concern basis, which implies the Company will continue to realize its assets and discharge its liabilities in the normal course of business.  The Company has not generated revenue since its inception and is unlikely to generate earnings in the immediate or foreseeable future.  The continuation of the Company as a going concern is dependent upon the continued financial support from its shareholders and the ability of the Company to obtain necessary equity financing to continue operations and the attainment of profitable operations.  As of September 30, 2009, the Company has accumulated losses since inception.  These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.  These factors raise substantial doubt regarding the Company's ability to continue as a going concern.

 Note 3.  Related Party Advances

During the three months ended June 30, 2010, a director advanced $4,176 to the Company for working capital purposes.  The advances do not bear interest and have no specified date of repayment.

Note 4.   Subsequent Events

On March 31, 2010, the Company approved the issuance of 1,600,000 shares of common stock to a director for services.

Note 5. Restatement

The Company inadvertently failed to record a year end journal entry when preparing its quarterly financial statements.  In addition, the Company inserted the incorrect audited financial statements for the year ended March 31, 2009.  As a result, common stock at March 31, 2009 and at quarter end was over stated by $6,000, additional paid-in capital was overstated by $174,000, and compensation expense, net loss, and accumulated deficit were overstated by $180,000 for the same periods.

6

ITEM 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of the Company’s financial condition as of September 30, 2009 and 2008, and its results of operations for the three months ended September 30, 2009 and 2008, and for period inception (May 9, 2007) through September 30, 2009, should be read in conjunction with the audited consolidated financial statements and notes included in Edgeline Holdings’ Form 10-K for the year ended March 31, 2009, filed with the Securities and Exchange Commission.

Overview

In January 2008, the Company determined to primarily focus its business on developing products to treat cancer, infectious diseases and other medical conditions associated with compromised immune systems.  As a development stage company, substantially all of the Company’s efforts will be devoted to performing research and experimentation, conducting clinical trials, developing and acquiring intellectual properties, raising capital and recruiting and training personnel.

Results of Operations – Inception (May 9, 2007) to September 30, 2009

The Company has had no revenue for period from inception (May 9, 2007) through September 30, 2009.

The Company’s expenses were $2,794,193, which were primarily comprised of compensation and related expenses of $1,009,324, professional fees of $853,388, investor relations expenses of $292,444, interest expense of $465,946 and other miscellaneous expenses of $292,026.

In addition to the foregoing expenses, the Company performed an impairment test on the carrying value of the license agreement it had acquired from Secure Voice Communications, Inc. (Florida) and determined an impairment charge for the full carrying value of $80,100 was warranted.  In connection with the license agreement acquisition, Secure Voice Communications, Inc. (Texas) issued a promissory note to Secure Voice Communications, Inc. (Florida) in the principal amount of $200,000.  This amount exceeded the estimated fair value of the license agreement of $80,100 and the excess amount of $119,900 was charged to compensation expense.

In November 2007, the Company issued 500,000 shares of its restricted common stock to the shareholders of Intertech Bio Corporation for 100% of the capital stock of Intertech Bio, with Intertech Bio becoming a wholly-owned subsidiary of the Company.  Based upon the fair market value on the date of acquisition, the Company valued the common stock issued at $220,000 and charged the entire amount to acquisition costs during the quarter ended September 30, 2008.

As a result of the foregoing, the Company’s net operating loss for the period inception (May 9, 2007) through September 30, 2009 was $2,794,193.

Comparison of Three Months Ended September 30, 2009 and 2008.

The Company has had no revenue for the three months ended September 30, 2009 and 2008.

The Company’s expenses decreased from $189,400 for three months ended September 30, 2008 to $258 for the three months ended September 30, 2009.  The decrease was attributed to the low activity in 2009.

As a result of the foregoing, the Company’s net loss for the three months ended September 30, 2009 totaled $2,660 and the net loss for the same period in 2008 was $250,852.

Comparison of Six Months Ended September 30, 2009 and 2008.

The Company has had no revenue for the six months ended September 30, 2009 and 2008.

7

The Company’s expenses decreased from $456,648 for six months ended September 30, 2008 to $4,030 for the six months ended September 30, 2009.  The decrease was attributed to the low activity in 2009.

As a result of the foregoing, the Company’s net loss for the three months ended September 30, 2009 totaled $8,808 and the net loss for the same period in 2008 was $547,486.

Liquidity and Capital Resources

As of September 30, 2009, the Company had cash in non-restrictive accounts of $14 and negative working capital of $459,683.

Net cash used in operating activities for the six months ended September 30, 2009 was $4,462 compared to $154,666 for same period in 2008.

For the three months ended September 30, 2000, cash provided by financing activities totaled $4,176 compared to $157,239 for same period in 2008.

The Company needs to obtain significant additional capital resources through equity and/or debt financings.  As of September 30, 2009, the Company had minimal assets in cash and cash equivalents and negative working capital.  The Company can provide no assurance it will be successful in seeking this or any additional financing, and the failure to obtain any such financing may cause it to curtail its operations.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Pursuant to Item 305(e) of Regulation S-K (§ 229.305(e)), the Company is not required to provide the information required by this Item as it is a “smaller reporting company,” as defined by Rule 229.10(f)(1).

ITEM 4. CONTROLS AND PROCEDURES

(a) Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this Quarterly Report on Form 10-Q, we conducted an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”) of our disclosure controls and procedures (as defined in Rules13a-15(e) and 15d-15(e) under the Exchange Act). Based on this evaluation, the CEO and CFO concluded that our disclosure controls and procedures were not effective as of September 30, 2009 due to a lack of segregation of duties and an overreliance on consultants in the accounting and financial reporting process.

(b) Changes in Internal Controls Over Financial Reporting

There were no changes that occurred during the quarter covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

8

PART II.  OTHER INFORMATION

ITEM 6. EXHIBITS

Exhibit No.	Description
31.1	Certification of J. Leonard Ivins.
32.1	Certification for Sarbanes-Oxley Act of J. Leonard Ivins.

9

EX-31.1

EXHIBIT 31.1

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized

ONCOLIN THERAPEUTICS, INC.

By:  /s/ J. Leonard Ivins

J. Leonard Ivins, Chief Executive Officer

Date: May 19, 2010

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

Signature	Title	Date
/s/ J. Leonard Ivins	Chief Executive Officer and	May 19, 2010
J. Leonard Ivins	Chairman of the Board

EX-32.1

EXHIBIT 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, J. Leonard Ivins, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q/A of Oncolin Therapeutics, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the small business issuer and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation;

c) Evaluated the effectiveness of the small business issuer's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;

d) Disclosed in this report any change in the small business issuer's internal control over financial reporting that occurred during the small business issuer's most recent fiscal quarter (the small business issuer's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the small business issuer's internal control over financial reporting; and

5. I have disclosed, based on, my most recent evaluation of internal control over financial reporting to the small business issuer's auditors and the audit committee of the small business issuer's board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the small business issuer's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the small business issuer's internal control over financial reporting.

Date:  May 19, 2010
By:	/s/ J. Leonard Ivins
	J. Leonard Ivins
	Chief Executive Officer